| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
We identified roles for Fibroblast Growth Factor Receptor 2 (FGFR2)isoform IIIc in EEC carcinogenesis and demonstrated its diagnostic and prognostic values in EEC. Compared to high expression in atypical hyperplasia, Grade 1 (G1), and Grade 2 (G2) EEC tissues, Grade 3 (G3) EEC tissue showed low FGFR2IIIc expression (P <0.05). These results suggest that altered FGFR2IIIc expression plays an important role in EEC carcinogenesis. Some G3 EECs may develop through different carcinogenic processes than G1 and G2 EECs.
With the aim of identifying diagnostic and treatment biomarkers for EEC, we analyzed protein expression of EECs using proteomix. Although we could not identify high FGFR2IIIc expression in EEC tissues, 14 proteins showed upregulation in G3 EECs comapared to G1 and G2 EECs. These results may help in the identification of novel potential therapeutic target in EECs.
|
